Ibogaine Treatment in New Zealand

If you want to know whether legalisation makes ibogaine safe, New Zealand is the only place with an answer, because it is the only place that tried.

What the status actually is

Ibogaine and noribogaine are prescription medicines, listed in Schedule 1 Part 1 of the Medicines Regulations 1984. They are not controlled drugs: the Misuse of Drugs Act schedules psilocybin, LSD and mescaline, and does not schedule ibogaine.

They are also unapproved medicines, meaning no ibogaine product has been assessed and consented for marketing. Prescription-only status without an approved product is an unusual combination, and it is the whole New Zealand situation in one line: a doctor may prescribe it, and nobody has ever evaluated what they are prescribing.

The classification committee recommended it in November 2009 with an explicit rationale, and its reasoning is worth reading because it is a regulator thinking aloud:

Given its use for the therapeutic purpose of managing/treating addiction and the need for this treatment to be under supervision, Medsafe believed that there was a case for classifying ibogaine and its metabolite noribogaine as prescription medicines. This would not necessarily restrict the medical use in a therapeutic environment but would limit attempts at self treatment.

Note that the aim was to prevent people doing it alone, not to endorse doing it. Ibogaine in New Zealand covers the legal detail.

The route, and a change most sources have missed

Two provisions of the Medicines Act 1981 do the work. Section 25 lets an authorised prescriber procure, administer or arrange the administration of an unapproved medicine, including by direct importation, but only for patients identified at the time of import and never in bulk. Section 29 permits supply to a specified practitioner for a patient currently under their care.

Section 29 changed on 19 November 2025. Before that date the class was medical practitioners only. It now reads:

specified practitioner means— (a) a medical practitioner; or (b) a nurse practitioner; or (c) a pharmacist prescriber.

Any page written from earlier sources gets this wrong.

The audit trail, which is genuinely the best anywhere

This is what distinguishes New Zealand from every other destination, and it is worth understanding because it is the thing an unregulated jurisdiction cannot offer.

Section 29B, inserted in November 2025, requires the importer or manufacturer to report to the Director-General, in writing, as soon as practicable after the end of every month in which they supplied: the trade and generic name, dose form, strength, pack size, month and year of supply, and quantity.

They must also keep a record of the name of the prescriber, the name of the patient, and the place of supply, and provide those on request.

Supply under these sections may be audited as part of a wholesale or pharmacy licence.

The case that shows the limit

In 2013 a woman of 45 died on the fifth day of treatment at a clinic run by Iboga New Zealand Limited. The Health and Disability Commissioner published its findings in 2015, finding breaches by the doctor, by an assistant and by the company, which did not operate safely.

The details are on red flags: one page of documented procedures, 2,200 mg given against the clinic’s own maximum of 1,600 with no recorded rationale, no observations after 4.11pm, and the doctor leaving the premises five hours after the final dose.

And the supply was lawful. The decision records that Medsafe advised the Commissioner that ibogaine was imported and supplied to the doctor in accordance with the requirements of the Medicines Act.

That is the sentence that answers the question this page exists for. The legal machinery worked exactly as designed, every reporting duty was met, and a woman still died. Legality regulates who may supply. It does not regulate whether anyone is watching the monitor.

The Commissioner was careful about causation and so are we: it is the coroner’s role, not the Commissioner’s, to establish cause of death. The post-mortem recorded a strong possibility that the death was related to ibogaine ingestion and most probably to a cardiac arrhythmia.

And the outcome study

The only published outcome study from the country followed 14 people treated by two providers. Its abstract contains the sentence:

One patient enrolled in the study died during treatment.

Of the fourteen analysed, eight completed all interviews to twelve months on the primary drug-use measure. One of its two providers was a registered addictions counsellor rather than a physician, and supplied thirteen of the fourteen participants.

The paper also records that official reporting was voluntary at the time, that the two providers together reported treating 83 patients between 2012 and 2015, and that the true figure was probably above a hundred.

Why there is no success rate sets out what those denominators mean.

What to take from the one legal case

New Zealand is the strongest argument both for and against the idea that regulation solves this.

For: there is a named prescriber, a reporting chain, an auditable supply route, and a regulator that investigated and published when someone died. None of that exists in the destinations most people actually travel to.

Against: it happened anyway, in a lawful chain, at a clinic with an experienced doctor. And the country’s own published cohort of fourteen contains a death.

How to evaluate a clinic is the response to both halves.